Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -35.08% is 50% above its 5-year average of -69.90%, near the high end of its 5-year range (-158.97%–-11.79%).
33.45% above its 12-month average of -52.71%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -71.22%.
EBITDA MARGIN
-35.08%
EBITDA MARGIN AVG TTM
-52.71%
EBITDA MARGIN AVG 3Y
-72.53%
EBITDA MARGIN AVG 5Y
-69.90%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+33.45%
CURRENT VS 3Y AVG
+51.64%
CURRENT VS 5Y AVG
+49.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
908 Devices Inc.
Market Cap
$509.35M
EBITDA Margin
-35.08%
TTM Avg
-52.71%
3Y Avg
-72.53%
5Y Avg
-69.90%
Market Cap
$508.17M
EBITDA Margin
-1179818.18%
TTM Avg
-754929.09%
3Y Avg
-428982.67%
5Y Avg
-428982.67%
Market Cap
$510.36M
EBITDA Margin
-1406.75%
TTM Avg
-1406.75%
3Y Avg
-151851.64%
5Y Avg
-92301.39%
Market Cap
$517.09M
EBITDA Margin
-230187.80%
TTM Avg
-372428.90%
3Y Avg
-255754.79%
5Y Avg
-154022.75%
Market Cap
$493.94M
EBITDA Margin
-10611.95%
TTM Avg
-10611.95%
3Y Avg
-10611.95%
5Y Avg
-10611.95%
Market Cap
$493.28M
EBITDA Margin
-9.71%
TTM Avg
-10.19%
3Y Avg
-20.82%
5Y Avg
-63.11%
Market Cap
$486.60M
EBITDA Margin
21.12%
TTM Avg
19.78%
3Y Avg
18.26%
5Y Avg
11.49%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 908 Devices Inc. (MASS) | $509.35M | -35.08% | -52.71% | -72.53% | -69.90% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $508.17M | -1179818.18% | -754929.09% | -428982.67% | -428982.67% |
| Crescent Biopharma, Inc. (CBIO)vs › | $510.36M | -1406.75% | -1406.75% | -151851.64% | -92301.39% |
| Altimmune, Inc. (ALT)vs › | $517.09M | -230187.80% | -372428.90% | -255754.79% | -154022.75% |
| Monopar Therapeutics Inc. (MNPR)vs › | $521.82M | N/A | N/A | N/A | N/A |
| Oculis Holding AG (OCS)vs › | $493.94M | -10611.95% | -10611.95% | -10611.95% | -10611.95% |
| Evolus, Inc. (EOLS)vs › | $493.28M | -9.71% | -10.19% | -20.82% | -63.11% |
| Immix Biopharma, Inc. (IMMX)vs › | $525.76M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.60M | 21.12% | 19.78% | 18.26% | 11.49% |
| ProKidney Corp. (PROK)vs › | $536.32M | -17741.55% | -126136.56% | -126136.56% | -126136.56% |
Gross Margin
49.8%
EBITDA Margin
-35.1%
Operating Margin
-46.0%
Net Margin
-56.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -71.22% |
| 2026-03-31 | -40.09% |
| 2025-12-31 | -11.79% |
| 2025-09-30 | -31.60% |
| 2025-06-30 | -108.85% |
| 2025-03-31 | -82.66% |
| 2024-12-31 | -99.98% |
| 2024-09-30 | -158.97% |
| 2024-06-30 | -70.10% |
| 2024-03-31 | -84.65% |
| 2023-12-31 | -64.86% |
| 2023-09-30 | -58.40% |
| 2023-06-30 | -85.45% |
| 2023-03-31 | -130.53% |
| 2022-12-31 | -83.84% |
| 2022-09-30 | -42.38% |
| 2022-06-30 | -72.56% |
| 2022-03-31 | -111.41% |
| 2021-12-31 | -20.45% |
| 2021-09-30 | -39.98% |
| 2021-06-30 | -87.19% |
| 2021-03-31 | -102.35% |
| 2020-12-31 | -64.11% |
| 2020-09-30 | -18.06% |
| 2020-06-30 | 20.96% |
| 2020-03-31 | -63.96% |
| 2019-12-31 | -1.16% |
| 2019-09-30 | -115.38% |
| 2019-06-30 | -115.49% |
| 2019-03-31 | -116.07% |
